{"success":true,"data":{"pressRelease":{"id":"141838","rtpr_id":"nGNE86vdX6-20260911","ticker":"RNAQU","exchange":"NASDAQ","all_tickers":["RNAQU"],"title":"Rainier Acquisition Corporation Announces Separation of Its Class A Ordinary Shares and Warrants on Nasdaq, Commencing September 14, 2026","author":"Globe Newswire","published_at":"2026-09-11T20:29:59.936Z","article_body":"The Class A ordinary shares will trade under the symbol “RNAQ” and the\nwarrants under the symbol “RNAQW” on The Nasdaq Capital Market, while\nunits that are not separated will continue to trade under the symbol\n“RNAQU.”\n\nNEW YORK, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition\nCorporation (Nasdaq: RNAQU) (the “Company”) announced today that,\ncommencing September 14, 2026, holders of the units sold in its initial public\noffering (the “Units”) may elect to separately trade the Class A ordinary\nshares and warrants included in the Units. Each Unit consists of one Class A\nordinary share and one-quarter of one redeemable warrant. No fractional\nwarrants will be issued upon separation of the Units, and only whole warrants\nwill trade. Each whole warrant entitles the holder thereof to purchase one\nClass A ordinary share at a price of $11.50 per share, subject to certain\nadjustments. Only whole warrants are exercisable.\n\nThe Class A ordinary shares and warrants that are separated will begin trading\non The Nasdaq Capital Market (“Nasdaq”) on September 15, 2026 under the\nsymbols “RNAQ” and “RNAQW,” respectively. Units that are not separated\nwill continue to trade on Nasdaq under the symbol “RNAQU.” Holders of\nUnits will need to have their brokers contact Continental Stock Transfer &\nTrust Company, the Company’s transfer agent, in order to separate the Units\ninto Class A ordinary shares and warrants.\n\nThe Units began trading on Nasdaq on August 27, 2026. The Company’s initial\npublic offering, including the full exercise of the underwriter’s\nover-allotment option, totaled 8,625,000 Units and generated gross proceeds of\n$86,250,000, before underwriting discounts and offering expenses, and an\naggregate of $86,250,000 ($10.00 per Unit) was placed in the Company’s trust\naccount. Chardan Capital Markets LLC (“Chardan”) acted as the sole\nbook-running manager for the offering.\n\nAbout Rainier Acquisition Corporation\n\nRainier Acquisition Corporation (Nasdaq: RNAQU, RNAQ, RNAQW) is a special\npurpose acquisition company formed for the purpose of effecting a merger,\namalgamation, share exchange, asset acquisition, share purchase,\nreorganization or similar business combination with one or more businesses.\nThe Company intends to focus its search on the global life sciences\nindustries, including therapeutics, diagnostics, genomics, precision medicine,\nlife science tools, research services, biomanufacturing, and related\nsubsectors, although its efforts to identify a prospective target business\nwill not be limited to any particular industry or geographical region. The\nCompany’s management team is led by Gbola Amusa, MD, CFA, Chief Executive\nOfficer, and Guy Barudin, Chief Financial Officer. The Company’s filings\nwith the U.S. Securities and Exchange Commission (the “SEC”) are available\nat www.sec.gov.\n\nThe offering was made only by means of a prospectus. Copies of the prospectus\nmay be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New\nYork 10119, or by email at prospectus@chardan.com.\n\nA registration statement relating to these securities was declared effective\nby the SEC on August 26, 2026. This press release shall not constitute an\noffer to sell or the solicitation of an offer to buy, nor shall there be any\nsale of these securities in any State or jurisdiction in which such an offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such State or jurisdiction.\n\nCautionary Note Concerning Forward-Looking Statements\n\nThis press release includes forward-looking statements that involve risks and\nuncertainties, including with respect to the timing of separate trading and\nthe Company’s search for an initial business combination. Forward-looking\nstatements are statements that are not historical facts. Such forward-looking\nstatements are subject to risks and uncertainties, which could cause actual\nresults to differ from the forward-looking statements. The Company expressly\ndisclaims any obligation or undertaking to release publicly any updates or\nrevisions to any forward-looking statements contained herein to reflect any\nchange in the Company’s expectations with respect thereto or any change in\nevents, conditions or circumstances on which any statement is based.\nForward-looking statements are subject to numerous conditions, many of which\nare beyond the control of the Company, including those set forth in the Risk\nFactors section of the Company’s registration statement and related\nprospectus for the Company’s initial public offering filed with the SEC.\nCopies of these documents are available on the SEC’s website, at\nwww.sec.gov. The Company undertakes no obligation to update these statements\nfor revisions or changes after the date of this release, except as required by\nlaw.\n\nContact:\nRainier Acquisition Corporation\nGbola Amusa, MD, CFA, Chief Executive Officer\n1 Pennsylvania Plaza, Suite 4800\nNew York, NY 10119\nTel.: (646) 465-9000\ngamusa@rainier-acq.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE86vdX6-20260911","title":"Rainier Acquisition Corporation Announces Separation of Its Class A Ordinary Shares and Warrants on Nasdaq, Commencing September 14, 2026","author":"Globe Newswire","ticker":"RNAQU","created":"2026-09-11T20:29:59.936Z","tickers":["RNAQU"],"exchange":"NASDAQ","article_body":"The Class A ordinary shares will trade under the symbol “RNAQ” and the\nwarrants under the symbol “RNAQW” on The Nasdaq Capital Market, while\nunits that are not separated will continue to trade under the symbol\n“RNAQU.”\n\nNEW YORK, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition\nCorporation (Nasdaq: RNAQU) (the “Company”) announced today that,\ncommencing September 14, 2026, holders of the units sold in its initial public\noffering (the “Units”) may elect to separately trade the Class A ordinary\nshares and warrants included in the Units. Each Unit consists of one Class A\nordinary share and one-quarter of one redeemable warrant. No fractional\nwarrants will be issued upon separation of the Units, and only whole warrants\nwill trade. Each whole warrant entitles the holder thereof to purchase one\nClass A ordinary share at a price of $11.50 per share, subject to certain\nadjustments. Only whole warrants are exercisable.\n\nThe Class A ordinary shares and warrants that are separated will begin trading\non The Nasdaq Capital Market (“Nasdaq”) on September 15, 2026 under the\nsymbols “RNAQ” and “RNAQW,” respectively. Units that are not separated\nwill continue to trade on Nasdaq under the symbol “RNAQU.” Holders of\nUnits will need to have their brokers contact Continental Stock Transfer &\nTrust Company, the Company’s transfer agent, in order to separate the Units\ninto Class A ordinary shares and warrants.\n\nThe Units began trading on Nasdaq on August 27, 2026. The Company’s initial\npublic offering, including the full exercise of the underwriter’s\nover-allotment option, totaled 8,625,000 Units and generated gross proceeds of\n$86,250,000, before underwriting discounts and offering expenses, and an\naggregate of $86,250,000 ($10.00 per Unit) was placed in the Company’s trust\naccount. Chardan Capital Markets LLC (“Chardan”) acted as the sole\nbook-running manager for the offering.\n\nAbout Rainier Acquisition Corporation\n\nRainier Acquisition Corporation (Nasdaq: RNAQU, RNAQ, RNAQW) is a special\npurpose acquisition company formed for the purpose of effecting a merger,\namalgamation, share exchange, asset acquisition, share purchase,\nreorganization or similar business combination with one or more businesses.\nThe Company intends to focus its search on the global life sciences\nindustries, including therapeutics, diagnostics, genomics, precision medicine,\nlife science tools, research services, biomanufacturing, and related\nsubsectors, although its efforts to identify a prospective target business\nwill not be limited to any particular industry or geographical region. The\nCompany’s management team is led by Gbola Amusa, MD, CFA, Chief Executive\nOfficer, and Guy Barudin, Chief Financial Officer. The Company’s filings\nwith the U.S. Securities and Exchange Commission (the “SEC”) are available\nat www.sec.gov.\n\nThe offering was made only by means of a prospectus. Copies of the prospectus\nmay be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New\nYork 10119, or by email at prospectus@chardan.com.\n\nA registration statement relating to these securities was declared effective\nby the SEC on August 26, 2026. This press release shall not constitute an\noffer to sell or the solicitation of an offer to buy, nor shall there be any\nsale of these securities in any State or jurisdiction in which such an offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such State or jurisdiction.\n\nCautionary Note Concerning Forward-Looking Statements\n\nThis press release includes forward-looking statements that involve risks and\nuncertainties, including with respect to the timing of separate trading and\nthe Company’s search for an initial business combination. Forward-looking\nstatements are statements that are not historical facts. Such forward-looking\nstatements are subject to risks and uncertainties, which could cause actual\nresults to differ from the forward-looking statements. The Company expressly\ndisclaims any obligation or undertaking to release publicly any updates or\nrevisions to any forward-looking statements contained herein to reflect any\nchange in the Company’s expectations with respect thereto or any change in\nevents, conditions or circumstances on which any statement is based.\nForward-looking statements are subject to numerous conditions, many of which\nare beyond the control of the Company, including those set forth in the Risk\nFactors section of the Company’s registration statement and related\nprospectus for the Company’s initial public offering filed with the SEC.\nCopies of these documents are available on the SEC’s website, at\nwww.sec.gov. The Company undertakes no obligation to update these statements\nfor revisions or changes after the date of this release, except as required by\nlaw.\n\nContact:\nRainier Acquisition Corporation\nGbola Amusa, MD, CFA, Chief Executive Officer\n1 Pennsylvania Plaza, Suite 4800\nNew York, NY 10119\nTel.: (646) 465-9000\ngamusa@rainier-acq.com"},"type":"article","timestamp":"2026-09-11T20:30:00.037532607Z","server_sent_at_ms":1789158600037},"received_at":"2026-09-11T20:30:00.093Z","source_url":null},"analysis":{"id":"130670","press_release_id":"141838","analysis_json":{"industry":null,"redFlags":[],"eventType":"other","narrative":"Rainier Acquisition Corporation said that, commencing September 14, 2026, holders of its IPO units may elect to separately trade the Class A ordinary shares and warrants, with separated securities trading on Nasdaq under RNAQ and RNAQW from September 15 while unseparated units remain RNAQU.\n\nEach unit consists of one Class A ordinary share and one-quarter of one redeemable warrant; only whole warrants will trade and each whole warrant is exercisable at $11.50 per share.\n\nThe IPO, including full exercise of the underwriter's over-allotment, totaled 8,625,000 units and generated gross proceeds of $86,250,000, all of which was placed in trust at $10.00 per unit; Chardan Capital Markets acted as sole book-running manager.\n\nRainier is a pre-deal SPAC searching for life sciences targets, so the separation is a routine structural step that does not change unit economics or the status of the deal search.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Standard SPAC unit separation -- informational only, no impact on trust value or deal timeline."},"keyFigures":{"customDimensions":{"units_sold":8625000,"gross_proceeds":"$86,250,000","trust_per_unit":"$10.00","unit_composition":"one Class A ordinary share plus one-quarter of one redeemable warrant","ipo_trading_start":"August 27, 2026","reg_effective_date":"August 26, 2026","trust_account_balance":"$86,250,000","separate_trading_start":"September 15, 2026","warrant_exercise_price":11.5,"separation_election_start":"September 14, 2026"}},"namedEntities":{"people":[{"name":"Gbola Amusa, MD, CFA","role":"Chief Executive Officer"},{"name":"Guy Barudin","role":"Chief Financial Officer"}],"products":[],"companies":[{"name":"Rainier Acquisition Corporation","ticker":"RNAQU","relationship":"filer"},{"name":"Chardan Capital Markets LLC","relationship":"sole book-running manager for the IPO"},{"name":"Continental Stock Transfer & Trust Company","relationship":"transfer agent"}],"dollarAmounts":[{"amount":"$86,250,000","context":"gross proceeds from the IPO of 8,625,000 Units, before underwriting discounts and offering expenses"},{"amount":"$86,250,000","context":"aggregate placed in the Company's trust account at $10.00 per Unit"},{"amount":"$11.50","context":"exercise price for one Class A ordinary share per whole warrant"}]},"materialImpact":{"score":2,"reasoning":"Routine post-IPO SPAC mechanics: units become separately tradable into Class A shares and warrants, which is a standard structural step with no change to the trust, unit economics, or the pre-deal status of the company."},"tickerRelevance":{"others":[{"ticker":"RNAQ","relevance":"new ticker for the filer's separately traded Class A ordinary shares"},{"ticker":"RNAQW","relevance":"new ticker for the filer's separately traded warrants"}],"primary":"RNAQU"},"globalImportance":8,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"dealStage":"pre-deal / no target announced","tickerTier":"micro-cap pre-deal SPAC","eventGravity":"routine unit separation mechanics","consumerAngle":"none","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Rainier Acquisition Corporation said that, commencing September 14, 2026, holders of its IPO units may elect to separately trade the Class A ordinary shares and warrants, with separated securities trading on Nasdaq under RNAQ and RNAQW from September 15 while unseparated units remain RNAQU.\n\nEach unit consists of one Class A ordinary share and one-quarter of one redeemable warrant; only whole warrants will trade and each whole warrant is exercisable at $11.50 per share.\n\nThe IPO, including full exercise of the underwriter's over-allotment, totaled 8,625,000 units and generated gross proceeds of $86,250,000, all of which was placed in trust at $10.00 per unit; Chardan Capital Markets acted as sole book-running manager.\n\nRainier is a pre-deal SPAC searching for life sciences targets, so the separation is a routine structural step that does not change unit economics or the status of the deal search.","key_figures":{"customDimensions":{"units_sold":8625000,"gross_proceeds":"$86,250,000","trust_per_unit":"$10.00","unit_composition":"one Class A ordinary share plus one-quarter of one redeemable warrant","ipo_trading_start":"August 27, 2026","reg_effective_date":"August 26, 2026","trust_account_balance":"$86,250,000","separate_trading_start":"September 15, 2026","warrant_exercise_price":11.5,"separation_election_start":"September 14, 2026"}},"named_entities":{"people":[{"name":"Gbola Amusa, MD, CFA","role":"Chief Executive Officer"},{"name":"Guy Barudin","role":"Chief Financial Officer"}],"products":[],"companies":[{"name":"Rainier Acquisition Corporation","ticker":"RNAQU","relationship":"filer"},{"name":"Chardan Capital Markets LLC","relationship":"sole book-running manager for the IPO"},{"name":"Continental Stock Transfer & Trust Company","relationship":"transfer agent"}],"dollarAmounts":[{"amount":"$86,250,000","context":"gross proceeds from the IPO of 8,625,000 Units, before underwriting discounts and offering expenses"},{"amount":"$86,250,000","context":"aggregate placed in the Company's trust account at $10.00 per Unit"},{"amount":"$11.50","context":"exercise price for one Class A ordinary share per whole warrant"}]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-11T20:30:24.263Z","global_importance":8,"audience_relevance":8,"importance_components":{"dealStage":"pre-deal / no target announced","tickerTier":"micro-cap pre-deal SPAC","eventGravity":"routine unit separation mechanics","consumerAngle":"none","issuerAuthored":true}},"durationMs":24166,"modelName":"glm-5.3-flash"}}